Following the rise in Mpox cases, particularly in countries where the disease had not traditionally been observed, the World ...

IDT played a pivotal role in manufacturing the personalized gene editing therapy given to baby KJ Muldoon to treat his rare ...

The ethics of using safe gene therapies to improve the health and cognition of Down syndrome children and adults.

India has developed BIRSA 101, its first indigenous CRISPR gene therapy for sickle cell disease, using a more precise ...

CRISPR Therapeutics proved the strength of its technology a couple of years ago when it won approval for its first product.

The U.S. FDA has begun piloting real-time clinical trial tracking in two cancer studies to speed up safety and efficacy monitoring. The move comes as CRISPR Therapeutics attracts investor attention ...

Non-model crop species represent a vast and diverse component of global agriculture, forestry, and horticulture, yet they are routinely underrepresented in ...

Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the ...

Two papers published in The New England Journal of Medicine highlight the potential of gene editing for treatment of sickle ...

With Phase 3 data in hand, Intellia Therapeutics is seeking approval for its in vivo CRISPR gene editing therapy for ...

Intellia also separately announced positive topline data today from the Phase 3 HAELO clinical trial of lonvo-z in HAE. The trial met its primary and all key secondary endpoints, demonstrating that a ...

Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...